Abe N, Watanabe T, Izumisato Y, Suzuki Y, Masaki T, Mori T, Sugiyama M, Fusco A, Atomi Y (2003a) High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. J Gastroenterol 38: 1144-1149.
Abe N, Watanabe T, Sugiyama M, Uchimura H, Chiappetta G, Fusco A, Atomi Y (1999) Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res 59: 1169-1174.
Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A, Atomi Y (2003b) An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 89: 2104-2109.
Agresti A, Bianchi ME (2003) HMGB proteins and gene expression. Curr Opin Genet Dev 13: 170-178.
Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570.
Andrieux J, Demory JL, Dupriez B, Quief S, Plantier I, Roumier C, Bauters F, Lai JL, Kerckaert JP (2004) Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 39: 82-87.
Ayoubi TA, Jansen E, Meulemans SM, Van de Ven WJ (1999) Regulation of HMGIC expression: an architectural transcription factor involved in growth control and development. Oncogene 18: 5076-5087.
Bagga R, Michalowski S, Sabnis R, Griffith JD, Emerson BM (2000) HMG I/Y regulates long-range enhancer-dependent transcription on DNA and chromatin by changes in DNA topology. Nucleic Acids Res 28: 2541-2550.
Balcerczak M, Pasz-Walczak G, Balcerczak E, Wojtylak M, Kordek R, Mirowski M (2003) HMGI(Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging. Pathol Res Pract 199: 641-646.
Bandiera A, Bonifacio D, Manfioletti G, Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L, Giancotti V (1998) Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 58:
426-431.
Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E (2006) Common cancer biomarkers. Cancer Res 66: 2953-2961.
Bast RC, Jr., Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A (2005) Translational crossroads for biomarkers. Clin Cancer Res 11: 6103-6108.
Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM, Fusco A (1999) The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 59: 4793-4797.
Becker K, Murua Escobar H, Richter A, Meyer B, Nolte I, Bullerdiek J (2003) The canine HMGA1 gene maps to CFA 23. Anim Genet 34: 68-69.
Begum N, Pash JM, Bhorjee JS (1990) Expression and synthesis of high mobility group chromosomal proteins in different rat skeletal cell lines during myogenesis. J Biol Chem 265: 11936-11941.
Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233: 212-214.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620-625.
Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V, Fusco A (1995) Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 15: 1545-1553.
Bianchi ME, Beltrame M, Paonessa G (1989) Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243: 1056-1059.
Bianchi ME, Falciola L, Ferrari S, Lilley DM (1992) The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. Embo J 11: 1055-1063.
Boo LM, Lin HH, Chung V, Zhou B, Louie SG, O'Reilly MA, Yen Y, Ann DK (2005) High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 65: 6622-6630.
Borrmann L, Schwanbeck R, Heyduk T, Seebeck B, Rogalla P, Bullerdiek J, Wisniewski JR (2003) High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity.
Nucleic Acids Res 31: 6841-6851.
Boutemmine D, Bouchard N, Boerboom D, Jones HE, Goff AK, Dore M, Sirois J (2002) Molecular characterization of canine prostaglandin G/H synthase-2 and regulation in prostatic adenocarcinoma cells in vitro. Endocrinology 143: 1134-1143.
Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. Faseb J 17: 1295-1297.
Bussemakers MJ, van de Ven WJ, Debruyne FM, Schalken JA (1991) Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res 51: 606-611.
Bustin M (1999) Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19: 5237-5246.
Bustin M (2001) Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 26: 152-153.
Bustin M, Reeves R (1996) High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 54: 35-100.
Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25: 169-193.
Bustin SA (2002) Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 29: 23-39.
Cabart P, Kalousek I, Jandova D, Hrkal Z (1995) Differential expression of nuclear HMG1, HMG2 proteins and H1(zero) histone in various blood cells. Cell Biochem Funct 13: 125-133.
Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, Bianchi ME (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 22: 276-280.
Chase MB, Haga SB, Hankins WD, Williams DM, Bi Z, Strovel JW, Obriecht C, Berg PE (1999) Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene. Am J Hematol 60: 27-35.
Chau KY, Patel UA, Lee KL, Lam HY, Crane-Robinson C (1995) The gene for the human architectural transcription factor HMGI-C consists of five exons each coding for a distinct functional element. Nucleic Acids Res 23: 4262-4266.
Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A, Fusco A (1996) High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13:
2439-2446.
Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V, Fusco A (1995) The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 10: 1307-1314.
Chiappetta G, Botti G, Monaco M, Pasquinelli R, Pentimalli F, Di Bonito M, D'Aiuto G, Fedele M, Iuliano R, Palmieri EA, Pierantoni GM, Giancotti V, Fusco A (2004) HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res 10: 7637-7644.
Chiappetta G, Manfioletti G, Pentimalli F, Abe N, Di Bonito M, Vento MT, Giuliano A, Fedele M, Viglietto G, Santoro M, Watanabe T, Giancotti V, Fusco A (2001) High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 91: 147-151.
Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V, Fusco A (1998) Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58: 4193-4198.
Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N (1997) New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 11: 1404-1428.
Crippa MP, Alfonso PJ, Bustin M (1992) Nucleosome core binding region of chromosomal protein HMG-17 acts as an independent functional domain. J Mol Biol 228: 442-449.
Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152: 1197-1206.
Diana F, Di Bernardo J, Sgarra R, Tessari MA, Rustighi A, Fusco A, Giancotti V, Manfioletti G (2005) Differential HMGA expression and post-translational modifications in prostatic tumor cells. Int J Oncol 26: 515-520.
Eliceiri BP, Klemke R, Stromblad S, Cheresh DA (1998) Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 140: 1255-1263.
Elton TS, Reeves R (1986) Purification and postsynthetic modifications of Friend erythroleukemic cell high mobility group protein HMG-I. Anal Biochem 157: 53-62.
Fabjani G, Tong D, Wolf A, Roka S, Leodolter S, Hoecker P, Fischer MB, Jakesz R, Zeillinger R (2005) HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep 14:
737-741.
Falvo JV, Thanos D, Maniatis T (1995) Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y).
Cell 83: 1101-1111.
Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M, Giancotti V, Fusco A (1996) Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 56: 1896-1901.
Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A (2002) Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21: 3190-3198.
Fedele M, Fidanza V, Battista S, Pentimalli F, Klein-Szanto AJ, Visone R, De Martino I, Curcio A, Morisco C, Del Vecchio L, Baldassarre G, Arra C, Viglietto G, Indolfi C, Croce CM, Fusco A (2006) Haploinsufficiency of the hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res 66: 2536-2543.
Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, Kenyon L, Visone R, De Martino I, Ciarmiello A, Arra C, Viglietto G, Croce CM, Fusco A (2005) Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24: 3427-3435.
Ferrari S, Finelli P, Rocchi M, Bianchi ME (1996) The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics 35: 367-371.
Fletcher JA, Longtine J, Wallace K, Mentzer SJ, Sugarbaker DJ (1995) Cytogenetic and histologic findings in 17 pulmonary chondroid hamartomas:
evidence for a pathogenetic relationship with lipomas and leiomyomas. Genes Chromosomes Cancer 12: 220-223.
Flohr AM, Rogalla P, Bonk U, Puettmann B, Buerger H, Gohla G, Packeisen J, Wosniok W, Loeschke S, Bullerdiek J (2003) High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 18: 999-1004.
Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J (2001) Variation of HMGB1 expression in breast cancer. Anticancer Res 21: 3881-3885.
Frantz S, Vincent KA, Feron O, Kelly RA (2005) Innate immunity and angiogenesis.
Circ Res 96: 15-26.
Friedmann M, Holth LT, Zoghbi HY, Reeves R (1993) Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 21: 4259-4267.
Gattas GJ, Quade BJ, Nowak RA, Morton CC (1999) HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 25:
316-322.
Goodwin GH, Sanders C, Johns EW (1973) A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 38: 14-19.
Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K, Bullerdiek J, Morton CC (2003) HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 38: 68-79.
Grosschedl R, Giese K, Pagel J (1994) HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet 10: 94-100.
Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
Hauke S, Flohr AM, Rogalla P, Bullerdiek J (2002) Sequencing of intron 3 of HMGA2 uncovers the existence of a novel exon. Genes Chromosomes Cancer 34:
17-23.
He Q, Liang CH, Lippard SJ (2000) Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A 97: 5768-5772.
Hehlmann R, Berger U, Hochhaus A (2005) Chronic myeloid leukemia: a model for oncology. Ann Hematol 84: 487-497.
Hennig Y, Rogalla P, Wanschura S, Frey G, Deichert U, Bartnitzke S, Bullerdiek J (1997) HMGIC expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12q14-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality. Cancer Genet Cytogenet 96: 129-133.
Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H (1998) The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 23: 350-357.
Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761.
Hou FF, Ren H, Owen WF, Jr., Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X (2004) Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15: 1889-1896.
Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 91: 10394-10398.
Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62: 4805-4811.
Inoue H, Nojima H, Okayama H (1990) High efficiency transformation of Escherichia coli with plasmids. Gene 96: 23-28.
Johns EW (1982) The HMG chromosomal proteins. Academic Press, London.
Johnson KR, Lehn DA, Reeves R (1989) Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y.
Mol Cell Biol 9: 2114-2123.
Junghanss C, Waak M, Knopp A, Kleine HD, Kundt G, Leithauser M, Hilgendorf I, Wolff D, Casper J, Freund M (2005) Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression. Neoplasma 52: 402-410.
Kanda Y, Hamaki T, Yamamoto R, Chizuka A, Suguro M, Matsuyama T, Takezako N, Miwa A, Kami M, Hirai H, Togawa A (2000) The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 88: 2529-2533.
Katz FE, Tindle R, Sutherland DR, Greaves MF (1985) Identification of a membrane glycoprotein associated with haemopoietic progenitor cells. Leuk Res 9:
191-198.
Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, Kohno K, Takenaka K, Sugimachi K, Kuwano M (1996) Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin.
Cancer Res 56: 5330-5333.
Kazmierczak B, Meyer-Bolte K, Tran KH, Wockel W, Breightman I, Rosigkeit J, Bartnitzke S, Bullerdiek J (1999) A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas.
Genes Chromosomes Cancer 26: 125-133.
Kazmierczak B, Wanschura S, Rommel B, Bartnitzke S, Bullerdiek J (1996) Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings. J Natl Cancer Inst 88: 1234-1236.
Kazmierczak B, Wanschura S, Rosigkeit J, Meyer-Bolte K, Uschinsky K, Haupt R, Schoenmakers EF, Bartnitzke S, Van de Ven WJ, Bullerdiek J (1995) Molecular characterization of 12q14-15 rearrangements in three pulmonary chondroid hamartomas. Cancer Res 55: 2497-2499.
Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, Salovaara R, Nissen AM, Salo J, Mattson K, Hollmen J, Knuutila S, Wikman H (2004) Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 149: 98-106.
Kim DH, Park YS, Park CJ, Son KC, Nam ES, Shin HS, Ryu JW, Kim DS, Park CK, Park YE (1999) Expression of the HMGI(Y) gene in human colorectal cancer. Int J Cancer 84: 376-380.
Kleihauer E, Kohne E (1978) Hämatologie: Physiologie, Pathologie, Klinik. Springer, Berlin u.a.
Klein-Hessling S, Schneider G, Heinfling A, Chuvpilo S, Serfling E (1996) HMG I(Y) interferes with the DNA binding of NF-AT factors and the induction of the interleukin 4 promoter in T cells. Proc Natl Acad Sci U S A 93: 15311-15316.
Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG (2002) Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 22: 5912-5922.
Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R (1985) The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 140: 230-238.
Knapp DW, Waters DJ (1997) Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today 3: 8-11.
Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61: 1-9.
Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:
1035-1042.
Kottickal LV, Sarada B, Ashar H, Chada K, Nagarajan L (1998) Preferential expression of HMGI-C isoforms lacking the acidic carboxy terminal in human leukemia. Biochem Biophys Res Commun 242: 452-456.
Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10: 445-448.
Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814.
Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O (2003) Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 88: 1406-1410.
Leek RD, Landers RJ, Harris AL, Lewis CE (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79: 991-995.
Lehn DA, Elton TS, Johnson KR, Reeves R (1988) A conformational study of the sequence specific binding of HMG-I (Y) with the bovine interleukin-2 cDNA. Biochem Int 16: 963-971.
Li D, Lin HH, McMahon M, Ma H, Ann DK (1997) Oncogenic raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells. J Biol Chem 272: 25062-25070.
Li G, Liu W, Frenz D (2006) Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology 27: 22-30.
Ligon AH, Moore SD, Parisi MA, Mealiffe ME, Harris DJ, Ferguson HL, Quade BJ, Morton CC (2005) Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. Am J Hum Genet 76: 340-348.
Liu WM, Guerra-Vladusic FK, Kurakata S, Lupu R, Kohwi-Shigematsu T (1999) HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Res 59: 5695-5703.
Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K (1995) Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 4: 357-362.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
MacEwen EG (1990) Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 9: 125-136.
Manfioletti G, Giancotti V, Bandiera A, Buratti E, Sautiere P, Cary P, Crane-Robinson C, Coles B, Goodwin GH (1991) cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res 19: 6793-6797.
Masciullo V, Baldassarre G, Pentimalli F, Berlingieri MT, Boccia A, Chiappetta G, Palazzo J, Manfioletti G, Giancotti V, Viglietto G, Scambia G, Fusco A (2003) HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24: 1191-1198.
Mello JA, Lippard SJ, Essigmann JM (1995) DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 34: 14783-14791.
Meyer B, Krisponeit D, Junghanss C, Murua Escobar H, Bullerdiek J (2006a) Quantitative expression analysis in peripheral blood of CML patients suggests correlation of HMGA2 expression and WBC status. (in Vorbereitung)
Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J (2006b) HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog (im Druck)
Meyer B, Murua Escobar H, Hauke S, Richter A, Winkler S, Rogalla P, Flohr AM, Bullerdiek J, Nolte I (2004a) Expression pattern of the HMGB1 gene in sarcomas of the dog. Anticancer Res 24: 707-710.
Meyer B, Murua Escobar H, Winkler S, Dolf G, Schelling C, Bullerdiek J, Nolte I (2004b) Molecular characterization and mapping of the canine cyclin D1 (CCND1) gene. Anim Genet 35: 413.
Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E, Presta M (2006) Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176: 12-15.
Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K (2004) Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity.
Cancer Res 64: 2024-2029.
Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA (1989) Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem 185: 303-310.
Muller S, Ronfani L, Bianchi ME (2004) Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332-343.
Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, Bianchi ME (2001) New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J 20: 4337-4340.
Murua Escobar H, Meyer B, Richter A, Becker K, Flohr AM, Bullerdiek J, Nolte I (2003) Molecular characterization of the canine HMGB1. Cytogenet Genome Res 101: 33-38.
Murua Escobar H, Soller JT, Richter A, Meyer B, Winkler S, Bullerdiek J, Nolte I (2005) "Best friends" sharing the HMGA1 gene: comparison of the human and canine HMGA1 to orthologous other species. J Hered 96: 777-781.
Murua Escobar H, Soller JT, Richter A, Meyer B, Winkler S, Flohr AM, Nolte I, Bullerdiek J (2004) The canine HMGA1. Gene 330: 93-99.
Nagatani G, Nomoto M, Takano H, Ise T, Kato K, Imamura T, Izumi H, Makishima K, Kohno K (2001) Transcriptional Activation of the Human HMG1 Gene in Cisplatin-resistant Human Cancer Cells. Cancer Res 61: 1592-1597.
Nagpal S, Ghosn C, DiSepio D, Molina Y, Sutter M, Klein ES, Chandraratna RA (1999) Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J Biol Chem 274: 22563-22568.
Nissen MS, Langan TA, Reeves R (1991) Phosphorylation by cdc2 kinase modulates DNA binding activity of high mobility group I nonhistone chromatin protein.
J Biol Chem 266: 19945-19952.
Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25: 85-109.
Odero MD, Grand FH, Iqbal S, Ross F, Roman JP, Vizmanos JL, Andrieux J, Lai JL, Calasanz MJ, Cross NC (2005) Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies.
Leukemia 19: 245-252.
Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z (2002) Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. Faseb J 16: 1928-1930.
Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164: 441-449.
Park IW, Wistuba, II, Maitra A, Milchgrub S, Virmani AK, Minna JD, Gazdar AF (1999) Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 91: 1863-1868.
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
Parkin DM, Pisani P, Lopez AD, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 59: 494-504.
Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, Rauvala H (1993) Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides.
Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 268: 19726-19738.
Patel HS, Kantarjian HM, Bueso-Ramos CE, Medeiros LJ, Haidar MA (2005) Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. Genes Chromosomes Cancer 42: 87-94.
Peiper SC, Ashmun RA, Look AT (1988) Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood 72: 314-321.
Pierantoni GM, Santulli B, Caliendo I, Pentimalli F, Chiappetta G, Zanesi N, Santoro M, Bulrich F, Fusco A (2003) HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. Int J Oncol 23: 363-367.
Pil PM, Chow CS, Lippard SJ (1993) High-mobility-group 1 protein mediates DNA bending as determined by ring closures. Proc Natl Acad Sci U S A 90: 9465-9469.
Pil PM, Lippard SJ (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256: 234-237.
Pinto AL, Lippard SJ (1985) Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II). Proc Natl Acad Sci U S A 82: 4616-4619.
Reeck GR, Isackson PJ, Teller DC (1982) Domain structure in high molecular weight high mobility group nonhistone chromatin proteins. Nature 300: 76-78.
Reeves R, Edberg DD, Li Y (2001) Architectural Transcription Factor HMGI(Y) Promotes Tumor Progression and Mesenchymal Transition of Human Epithelial Cells. Mol. Cell. Biol. 21: 575-594.
Reeves R, Nissen MS (1990) The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265: 8573-8582.
Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J (1996) HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149: 775-779.
Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J (1997) Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 19: 153-156.
Rogalla P, Drechsler K, Schroder-Babo W, Eberhardt K, Bullerdiek J (1998) HMGIC expression patterns in non-small lung cancer and surrounding tissue.
Anticancer Res 18: 3327-3330.
Rogalla P, Kazmierczak B, Flohr AM, Hauke S, Bullerdiek J (2000) Back to the roots of a new exon--the molecular archaeology of a SP100 splice variant. Genomics 63: 117-122.
Rommel B, Rogalla P, Jox A, Kalle CV, Kazmierczak B, Wolf J, Bullerdiek J (1997) HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma 26: 603-607.
Rouhiainen A, Kuja-Panula J, Wilkman E, Pakkanen J, Stenfors J, Tuominen RK, Lepantalo M, Carpen O, Parkkinen J, Rauvala H (2004) Regulation of monocyte migration by amphoterin (HMGB1). Blood 104: 1174-1182.